Herpes simplex glycoprotein DNA vaccine - Pharmadigm

Drug Profile

Herpes simplex glycoprotein DNA vaccine - Pharmadigm

Latest Information Update: 13 Jul 2001

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inflabloc Pharmaceuticals
  • Developer Inflabloc Pharmaceuticals; Nonindustrial source
  • Class Gene therapies; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Herpes simplex virus infections

Most Recent Events

  • 13 Jul 2001 No-Development-Reported for Herpes simplex virus infections in USA (Unknown route)
  • 30 Apr 1996 Preclinical development for Herpes simplex virus infections in USA (Unknown route)
  • 30 Apr 1996 An animal study has been added to the Viral Infections pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top